Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median...
Hence then, the article about final os analysis results from phase iii optitrop lung04 study of sacituzumab tirumotecan sac tmt presented at 2026 esmo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO )
Also on site :
- Anthropic Sued for Using Elvis Presley Music to Train AI Models
- Sephora’s Sleek New Skincare Tool Instantly Depuffs and Sculpts the Skin
- Japan’s Gulliver’s Kingdom opened in 1997 with $350 million in loans; a court auction sold it for about $12 million